AEON Biopharma, Inc. (AEON) company profile
Close on Nov 16, 2026Market cap $7.02MP/E –Yield –
About AEON Biopharma
Pharmaceutical Preparations, SIC 2834
AEON Biopharma, Inc. is a biopharmaceutical company focused on developing its lead drug candidate, ABP-450, as a biosimilar to Botox for debilitating medical conditions. The company advances ABP-450 through the biosimilar regulatory pathway exclusively for therapeutic indications rather than cosmetic uses. ABP-450 is a botulinum neurotoxin complex intended to treat disorders such as cervical dystonia, spasticity, and chronic migraine. AEON plans to market and distribute the treatment directly to healthcare providers, physicians, and health systems operating within physician-administered medical environments.
The company holds exclusive development and distribution rights for therapeutic uses of ABP-450 across the United States, Canada, the European Union, the United Kingdom, and select other international territories. The underlying drug substance is manufactured at a dedicated facility in South Korea by Daewoong Pharmaceutical. AEON conducts its operations primarily in the United States, where it concentrates its commercialization and regulatory activities, though the provided text does not disclose the specific city or state of its corporate headquarters.
Summary of the business section of AEON Biopharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- AEON Biopharma, Inc.
- Headquarters
- Aliso Viejo, CA
- Address
- 130 Vantis Drive, Suite 170 92656
- Phone
- (949) 354-6499
- Website
- aeonbiopharma.com
- Employees
- 8, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Diego, California
Stock & identifiers
- Ticker
- AEON
- Former tickers
- PMGM until Jul 24, 2023
- Exchange
- NYSE
- IPO date
- Feb 11, 2021
- Shares outstanding
- 50M, Aug 6, 2026
- Public float
- $8.70M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-72 reverse, Feb 26, 2025
- SEC CIK
- 1837607
- CUSIP
- 00791X209
- ISIN
- US00791X2099
- FIGI
- BBG00Z17HDW3
- Share class FIGI
- BBG00Z17HFQ5
- EIN
- 85-3940478
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert E. Bancroft | PRESIDENT & CEO, Director | 3,177,103 |
| John Bencich | CHIEF FINANCIAL OFFICER | 754,717 |
| Chad Oh | CHIEF MEDICAL OFFICER | 2,183,436 |
| Alexander Blair Wilson | CLO, CSO, and Corp Secretary | 2,183,005 |
| Jennifer Sy | PRINCIPAL ACCOUNTING OFFICER | 1,501,176 |
| Robert J. Palmisano | Director | 2,523,705 |
| Marc Forth | Director | 973,231 |
| Shelley B. Thunen | Director | 258,705 |
| Jost Fischer | Director | 489,469 |
| Eric G. Carter | Director | 258,705 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Robert Bancroft President and Chief Executive Officer | $286.44K | $157.38K | $88.20K | $21.84K | $553.86K | – |
| Marc Forth Former President and Chief Executive Officer | $135.62K | – | – | – | $135.62K | -97% |
| Chad Oh Chief Medical Officer | $425.00K | $316.77K | $640.00K | – | $1.38M | -40% |
| Alex Wilson Chief Legal Officer | $400.00K | $325.33K | $640.00K | – | $1.37M | -36% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Feb 11, 2021
- Offer price
- $10.00
- Securities offered
- 24,000,000
- Gross proceeds
- $240.00M
- Exchange
- Nasdaq
- First trading day
- Apr 12, 2021
- First-day close
- $9.65-3.5%
- Lock-up ends (est.)
- Oct 9, 2021
“Each unit has an offering price of $10.00 and consists of one share of Class A common stock and one-third of one redeemable warrant.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had eight employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?